Evotec SE (EVO) Earnings Call Analysis
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Earnings Reports
-
EVO (EVO) Q1 2026: Double-Digit D&PD Order Growth Sets Up H2 Recovery Amid Strategic Review
May 06, 2026
-
Evotech (EVO) Q4 2025: Just Biologics Grows 40%, Reshapes Margin Profile for 2026
April 13, 2026
-
EVO (EVO) Q3 2025: Sandoz Deal Unlocks $650M Upside, Shifts Biologics to Asset-Light Model
November 06, 2025